BNP Paribas upgraded shares of Zealand Pharma A/S (OTCMKTS:ZLDPF - Free Report) to a strong-buy rating in a report released on Tuesday morning,Zacks.com reports.
Separately, William Blair upgraded Zealand Pharma A/S from a "hold" rating to a "strong-buy" rating in a research report on Friday, March 7th.
Read Our Latest Research Report on Zealand Pharma A/S
Zealand Pharma A/S Price Performance
Shares of OTCMKTS:ZLDPF traded down $0.77 during midday trading on Tuesday, reaching $56.98. The company's stock had a trading volume of 569 shares, compared to its average volume of 949. The business's fifty day simple moving average is $64.93 and its 200-day simple moving average is $80.10. The company has a market capitalization of $4.05 billion, a P/E ratio of -22.88 and a beta of 0.68. The company has a debt-to-equity ratio of 0.03, a current ratio of 25.10 and a quick ratio of 25.07. Zealand Pharma A/S has a fifty-two week low of $54.95 and a fifty-two week high of $141.74.
Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.67) earnings per share for the quarter, topping analysts' consensus estimates of ($0.77) by $0.10. Zealand Pharma A/S had a negative net margin of 2,127.09% and a negative return on equity of 13.40%. The company had revenue of $1.14 million during the quarter, compared to the consensus estimate of $248.61 million. As a group, equities research analysts expect that Zealand Pharma A/S will post -2.19 EPS for the current fiscal year.
Zealand Pharma A/S Company Profile
(
Get Free Report)
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.
Recommended Stories
Before you consider Zealand Pharma A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zealand Pharma A/S wasn't on the list.
While Zealand Pharma A/S currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
